Quest Diagnostics (DGX) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.31 per share. This compares to earnings of $2.30 per share a year ago.
Quest Diagnostics raised its 2024 profit and revenue forecasts on Tuesday, banking on robust demand for its health tests.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.
Quest Diagnostics said on Wednesday it would acquire LifeLabs, a provider of community laboratory tests, from OMERS for about C$1.35 billion, or about $985 million.
Quest Diagnostics Inc. DGX, -0.33% said Wednesday it has entered a definitive agreement with pension fund OMERS to acquire LifeLabs, a Canadian provider of community laboratory services, for about C$1.35 billion ($985 million), including net debt. “Quest has supported laboratories, hospitals and academic centres in Canada with specialized testing services for over two decades, including during the COVID-19 pandemic,” said Jim Davis, Chairman and CEO of Secaucus, N.J.
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.